BC
ALNY icon

Burney Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Burney Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$960K Sell
3,190
-221
-6% -$66.7K 0.03% 357
2026
Q1 		$1.13M Sell
3,411
-1,171
-26% -$398K 0.04% 305
2025
Q4 		$1.82M Sell
4,582
-301
-6% -$133K 0.06% 260
2025
Q3 		$2.23M Sell
4,883
-259
-5% -$105K 0.07% 220
2025
Q2 		$1.68M Sell
5,142
-1,060
-17% -$293K 0.06% 250
2025
Q1 		$1.67M Sell
6,202
-19,536
-76% -$5.02M 0.06% 236
2024
Q4 		$6.06M Buy
25,738
+4,791
+23% +$1.26M 0.21% 100
2024
Q3 		$5.76M Sell
20,947
-4,492
-18% -$1.17M 0.2% 119
2024
Q2 		$6.18M Sell
25,439
-1,620
-6% -$256K 0.24% 105
2024
Q1 		$4.04M Buy
27,059
+21,325
+372% +$3.56M 0.15% 157
2023
Q4 		$1.1M Buy
+5,734
New +$977K 0.05% 314

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Burney Company's ALNY Position: Q2 2026 in Review

Burney Company reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.5% in Q2 2026, selling an estimated $66.7K and leaving 3,190 shares worth $960K. The position accounts for 0.03% of the portfolio, ranked #357.

Burney Company first reported a position in ALNY in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.18M in Q2 2024. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Burney Company held 3,190 shares of Alnylam Pharmaceuticals worth $960K as of Q2 2026.
  • Burney Company sold 221 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $66.7K.
  • Alnylam Pharmaceuticals made up 0.03% of Burney Company's portfolio in Q2 2026, its #357 holding.
  • Burney Company first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Burney Company's Alnylam Pharmaceuticals position peaked at $6.18M in Q2 2024.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Burney Company's 13F filing for Q2 2026, filed 15 Jul 2026.